Treace Comments on CMS’ 2025 Final Rule for Hospital Outpatient and ASC Settings

GlobeNewswire11-04

PONTE VEDRA, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2480330079?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/P6hGMj8S.d4QX_J5XP3TKg--~B/aD0yNzU7dz0xMzgxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/0d7caf879909ad0f6a14ab73d391f1a9","is_english":true,"pubTime":"2024-11-04 21:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2480330079","market":"us","top_or_hot":-1,"title":"Treace Comments on CMS’ 2025 Final Rule for Hospital Outpatient and ASC Settings","media":"GlobeNewswire","content":"<div>\n<p>PONTE VEDRA, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (\"Treace\" or the \"Company\") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/treace-comments-cms-2025-final-130000607.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Treace Comments on CMS’ 2025 Final Rule for Hospital Outpatient and ASC Settings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTreace Comments on CMS’ 2025 Final Rule for Hospital Outpatient and ASC Settings\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-04 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/treace-comments-cms-2025-final-130000607.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PONTE VEDRA, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (\"Treace\" or the \"Company\") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/treace-comments-cms-2025-final-130000607.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0077335932.USD","symbol_name":"FIDELITY AMERICAN GROWTH \"A\" INC","start_time":0,"source_url":"https://finance.yahoo.com/news/treace-comments-cms-2025-final-130000607.html","article_id":"2480330079","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/P6hGMj8S.d4QX_J5XP3TKg--~B/aD0yNzU7dz0xMzgxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/0d7caf879909ad0f6a14ab73d391f1a9"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480330079","pubTimestamp":1730725200,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"PONTE VEDRA, Fla., Nov. 04, 2024  -- Treace Medical Concepts, Inc.  , a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty and Adductoplasty Procedures, today commented on the recently released Centers for Medicare & Medicaid Services  Calendar Year 2025 Hospital Outpatient Prospective Payment System  and Ambulatory Surgical Center  Final Rule, effective January 1, 2025.The Final Rule and accompanying Addenda include the reassignment of Current Procedural Terminology  code 28297  to Ambulatory Payment Classification  code 5115 with a hospital outpatient payment rate of $12,867 for 2025. This represents an increase of $6,050, or 89%, over 2024. In the ASC setting, the 2025 payment is $9,820, an increase of 100%, compared to $4,900 for 2024.“As the pioneer of the market leading Lapiplasty 3D Bunion Correction System, we are pleased that the final rule recognizes the value that Lapidus","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","LU1366333091.USD":"FIDELITY GLOBAL FOCUS \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU2346227817.USD":"BGF SUSTAINABLE GLOBAL INFRASTRUCTURE \"A2\" (USD) ACC","LU2420271590.USD":"ALLIANZ SELECT INCOME AND GROWTH \"AT\" (USD) ACC","LU2637428348.USD":"NORDEA 1 GLOBAL SUSTAINABLE LISTED REAL ASSETS \"MP\" (USD) INC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","BK4082":"医疗保健设备","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","BK4588":"碎股","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","BK4208":"复合型公用事业","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","TMCI":"Treace Medical Concepts, Inc.","ASC":"Ardmore Shipping Corporation","CMS":"CMS能源","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","CPT":"卡姆登物业信托","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0157215616.USD":"FIDELITY GLOBAL FOCUS \"A\" INC","BK4539":"次新股","APC":"阿纳达科石油","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4144":"石油与天然气的储存和运输","BK4215":"住宅房地产投资信托"},"translate_title":"Treace对CMS 2025年医院门诊和ASC设置最终规则的评论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASC":1,"APC":1,"CPT":1,"CMS":1,"TMCI":0.9},"content_text":"PONTE VEDRA, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (\"Treace\" or the \"Company\") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today commented on the recently released Centers for Medicare & Medicaid Services (CMS) Calendar Year 2025 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Final Rule, effective January 1, 2025.\nThe Final Rule and accompanying Addenda include the reassignment of Current Procedural Terminology (CPT) code 28297 (a primary code used for Lapidus fusion and one typically used for Lapiplasty® procedure reimbursement) to Ambulatory Payment Classification (APC) code 5115 with a hospital outpatient payment rate of $12,867 for 2025. This represents an increase of $6,050, or 89%, over 2024. In the ASC setting, the 2025 payment is $9,820, an increase of 100%, compared to $4,900 for 2024.\n“As the pioneer of the market leading Lapiplasty® 3D Bunion Correction® System, we are pleased that the final rule recognizes the value that Lapidus fusion offers patients suffering from painful, lifestyle-limiting bunion deformities,” said John T. Treace, CEO and Founder of Treace.\nInternet Posting of Information\nTreace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.\nAbout Treace Medical Concepts\nTreace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.\nTo learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.\nContacts:Treace Medical ConceptsMark L. HairChief Financial Officermhair@treace.net(904) 373-5940\nInvestors:Gilmartin GroupVivian Cervantes IR@treace.net","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2480330079"}